Novartis reaches settlement in Zelnorm suits; Vermont to reconsider pharma restrictions?;

@FiercePharma: J&J plant overhaul prompts 300 layoffs. Article | Follow @FiercePharma

> Novartis (NVS) reached a tentative agreement to settle 124 lawsuits brought by people who claimed their use of the gastrointestinal drug Zelnorm caused heart-related injuries. Report

> Massachusetts seems poised to overturn its two-year-old law regulating the financial relationship between doctors and drug companies and concerns are brewing that a similar effort will launch in Vermont. Article

> Abbott Laboratories said it settled a patent-infringement lawsuit filed against Teva Pharmaceutical Industries over generic versions of the antibiotic Omnicef. News

> Mylan (Nasdaq:MYL) has received final FDA approval for a generic version of Boehringer Ingelheim's Catapres-TTS, a treatment for hypertension. Report

> Sanofi-Aventis launched its new prostate cancer drug Jevtana in the U.S. Story

> UCB Pharma's managing director Matthew Speers has been elected chair of the European Medicines Group, taking over from Nigel Brooksby of Sanofi-Aventis. Story

Biotech News

 @FierceBiotech: Biotech takes top spot in Q2 VC investment. Article | Follow @FierceBiotech

 @JohnCFierce: Vivus is down 57% from yesterday's close. Orexigen adown 10%, Arena up 15% with analysts scurrying to support the cleanest safety data. Follow @JohnCFierce

> Flush with cash, Achaogen continues antibiotic work. Item

> Concert pursues clinical data for drug delivery tech. News

> Australia's Coridon attracts billionaire investment. Story

> Ramius looks to buy out Cypress. Report

Biotech IT News

> Meta-analysis stands trial with Avandia. Story

> Group uses Internet, phone for trial recruitment. Article

> Scientists take on Web 2.0 cure claims. Item

> Sloppy dialysis app earns #2 in breach ranking. Story

> Report: Big pharma drives adoption of digital signatures. Article

> Early dialogue with regulators key in global trials. Report

And Finally... Some scientists say the older antibiotics may be one way to fight sometimes deadly bacteria that have become resistant to modern drugs. Report